Contributions
Abstract: EP1761
Type: ePoster
Abstract Category: Therapy - disease modifying - 29 Risk management for disease modifying treatments
Background: Although rebounds of disease activity (RA) after natalizumab withdrawal have been widely described, data about a possible reactivation of disease activity in patients treated with fingolimod (FTY) are limited. We analyse those patients of our Department that have discontinuated FTY treatment, we describe rebound cases and we try to establish possible predictors.
Methods: Retrospective study including patients with Relapsing Remitting Multiple Sclerosis (RRMS) treated with FTY in whom it has been discontinuated, permanently or not. We compare patients with RA after FYT suspension and those with no-RA. We describe demographic, clinical, therapeutic and analytical features before and after withdrawal.
Results: 20 patients were included, 18 women. Mean age 37.2 years (SD:8.3). The median EDSS at diagnosis was 1 (SD:0.6) and mean relapse rate at first year was 1.35 (SD:0.58). The mean disease duration until FTY was 8.5 (SD:6.1), with mean time under FYT therapy of 33 months (SD:14.3). Mean of annualized relapse rate improvement was 90%. Mean of peripheral blood lymphocytes under FYT therapy was 300/mm3 (SD:130). Corticosteroids were used during washout period in 70.6% of patients. There were 17 cases of permanent FYT withdrawal, 10 of them with RA. Mean time to RA was 37 days after withdrawal (DS:22.3). No RA was observed in temporary discontinuations. Patients with RA had lower peripheral blood lymphocyte. No association was found with age, body mass index EDSS, disease activity, immediately previous treatment or the reason of discontinuation.
Conclusion: RA after FYT withdrawal was common in our experience. Peripheral blood lymphocytes may be one possible predictor. Future studies are needed for better defining this hypothesis and other intercurrent factors.
Disclosure: No author has nothing to disclose
Abstract: EP1761
Type: ePoster
Abstract Category: Therapy - disease modifying - 29 Risk management for disease modifying treatments
Background: Although rebounds of disease activity (RA) after natalizumab withdrawal have been widely described, data about a possible reactivation of disease activity in patients treated with fingolimod (FTY) are limited. We analyse those patients of our Department that have discontinuated FTY treatment, we describe rebound cases and we try to establish possible predictors.
Methods: Retrospective study including patients with Relapsing Remitting Multiple Sclerosis (RRMS) treated with FTY in whom it has been discontinuated, permanently or not. We compare patients with RA after FYT suspension and those with no-RA. We describe demographic, clinical, therapeutic and analytical features before and after withdrawal.
Results: 20 patients were included, 18 women. Mean age 37.2 years (SD:8.3). The median EDSS at diagnosis was 1 (SD:0.6) and mean relapse rate at first year was 1.35 (SD:0.58). The mean disease duration until FTY was 8.5 (SD:6.1), with mean time under FYT therapy of 33 months (SD:14.3). Mean of annualized relapse rate improvement was 90%. Mean of peripheral blood lymphocytes under FYT therapy was 300/mm3 (SD:130). Corticosteroids were used during washout period in 70.6% of patients. There were 17 cases of permanent FYT withdrawal, 10 of them with RA. Mean time to RA was 37 days after withdrawal (DS:22.3). No RA was observed in temporary discontinuations. Patients with RA had lower peripheral blood lymphocyte. No association was found with age, body mass index EDSS, disease activity, immediately previous treatment or the reason of discontinuation.
Conclusion: RA after FYT withdrawal was common in our experience. Peripheral blood lymphocytes may be one possible predictor. Future studies are needed for better defining this hypothesis and other intercurrent factors.
Disclosure: No author has nothing to disclose